Abstract Cabergoline and bromocriptine are dopaminergic drugs deriving from ergot and used for treating hyperprolactinemic idiopathic disorders or pituitary adenomas, whose mechanism of action results from the reduction of prolactin secretion. Some reports in the literature show that cabergoline can cause valvular heart disease after long-term administration. We report the case of a patient diagnosed with macroprolactinoma who did interleaved use of cabergoline and bromocriptine and developed valvular abnormalities that did not exist before.